October 22, 2003

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.

Bookmark

Cite This Study

Kris et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd16275f91138675359c88 https://doi.org/https://doi.org/10.1001/jama.290.16.2149

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer2003 · 2,888 citations
2Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens2000 · 1,373 citations
3<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors2003 · 2,291 citations
4Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.1993 · 488 citations
5p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas2002 · 214 citations

Bookmark